Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization

Journal of Circulating Biomarkers

Volumn 4, Issue , 2015, Pages

  Werner, Shannon L ^a   Graf, Ryon P ^a   Landers, Mark ^a   Valenta, David T ^a   Schroeder, Matthew ^a   Greene, Stephanie B ^a   Bales, Natalee ^a   Dittamore, Ryan ^a   Marrinucci, Dena ^a  

^a Epic Sciences Inc   (United States)

Author keywords

Analytical Validation; Biomarker; Circulating Tumour Cells; Clinical Feasibility; CTC; CTM; Epic CTC Platform; Fluid Biopsy; Liquid Biopsy; Metastasis

Indexed keywords

EID: 85011699697     PISSN: None     EISSN: 18494544     Source Type: Journal    
DOI: 10.5772/60725     Document Type: Article

References (79)

1. Gupta G P, and Massague J, (2006) Cancer metastasis: Building a framework. Cell. 127: 679–95
2. Chaffer C L, and Weinberg R A, (2011) A perspective on cancer cell metastasis. Science. 331: 1559–64
3. Hanahan D, and Weinberg R A, (2011) Hallmarks of cancer: The next generation. Cell. 144: 646–74
4. Yu M, Bardia A, Wittner B S, Stott S L, Smas M E, Ting D T, Isakoff S J, Ciciliano J C, Wells M N, Shah A M, Concannon K F, Donaldson M C, Sequist L V, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber D A, and Maheswaran S, (2013) Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 339: 580–4
5. Miller M C, Doyle G V, and Terstappen L W, (2010) Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010: 617421
6. Ashworth T R, (1869) A case of cancer in which cells similar to those in the tumours were seen in the blood after death. The Medical Journal of Australia. 14: 146–147
7. Pantel K, and Alix-Panabieres C, (2013) Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 73: 6384–8
8. Burrell R A, McGranahan N, Bartek J, and Swanton C, (2013) The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 501: 338–345
9. Hiley C, de Bruin E C, McGranahan N, and Swanton C, (2014) Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol. 15: 453
10. de Bruin E C, McGranahan N, Mitter R, Salm M, Wedge D C, Yates L, Jamal-Hanjani M, Shafi S, Murugaesu N, Rowan A J, Gronroos E, Muhammad M A, Horswell S, Gerlinger M, Varela I, Jones D, Marshall J, Voet T, van Loo P, Rassl D M, Rintoul R C, Janes S M, Lee S M, Forster M, Ahmad T, Lawrence D, Falzon M, Capitanio A, Harkins T T, Lee C C, Tom W, Teefe E, Chen S C, Begum S, Rabinowitz A, Phillimore B, Spencer-Dene B, Stamp G, Szallasi Z, Matthews N, Stewart A, Campbell P, and Swanton C, (2014) Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 346: 251–6
11. Greaves M, and Maley C C, (2012) Clonal evolution in cancer. Nature. 481: 306–13
12. Hayes D F, Cristofanilli M, Budd G T, Ellis M J, Stopeck A, Miller M C, Matera J, Allard W J, Doyle G V, and Terstappen L W, (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 12: 4218–24
13. de Bono J S, Scher H I, Montgomery R B, Parker C, Miller M C, Tissing H, Doyle G V, Terstappen L W, Pienta K J, and Raghavan D, (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14: 6302–9
14. Cohen S J, Punt C J, Iannotti N, Saidman B H, Sabbath K D, Gabrail N Y, Picus J, Morse M, Mitchell E, Miller M C, Doyle G V, Tissing H, Terstappen L W, and Meropol N J, (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 26: 3213–21
15. Antonarakis E S, Lu C, Wang H, Luber B, Nakazawa M, Roeser J C, Chen Y, Mohammad T A, Chen Y, Fedor H L, Lotan T L, Zheng Q, de Marzo A M, Isaacs J T, Isaacs W B, Nadal R, Paller C J, Denmeade S R, Carducci M A, Eisenberger M A, and Luo J, (2014) AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 371: 1028–38
16. Yap T A, Lorente D, Omlin A, Olmos D, and de Bono J S, (2014) Circulating tumor cells: A multifunctional biomarker. Clin Cancer Res. 20: 2553–68
17. Parkinson D R, Dracopoli N, Petty B G, Compton C, Cristofanilli M, Deisseroth A, Hayes D F, Kapke G, Kumar P, Lee J, Liu M C, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose E A, Roadcap L T, Schade A E, Scher H I, Sigman C C, and Kelloff G J, (2012) Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 10: 138
18. Phillips K G, Kuhn P, and McCarty O J, (2014) Physical biology in cancer. 2. The physical biology of circulating tumor cells. Am J Physiol Cell Physiol. 306: C80–8
19. Phillips K G, Kolatkar A, Rees K J, Rigg R, Marrinucci D, Luttgen M, Bethel K, Kuhn P, and McCarty O J, (2012) Quantification of cellular volume and sub-cellular density fluctuations: Comparison of normal peripheral blood cells and circulating tumor cells identified in a breast cancer patient. Front Oncol. 2: 96
20. Rao C G, Chianese D, Doyle G V, Miller M C, Russell T, Sanders R A, Jr. and Terstappen L W, (2005) Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol. 27: 49–57
21. Mikolajczyk S D, Millar L S, Tsinberg P, Coutts S M, Zomorrodi M, Pham T, Bischoff F Z, and Pircher T J, (2011) Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood. J Oncol. 2011: 252361
22. Sieuwerts A M, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens J W, Gratama J W, Sleijfer S, and Foekens J A, (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 101: 61–6
23. Mendez M G, Kojima S, and Goldman R D, (2010) Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J. 24: 1838–51
24. Kalluri R, and Weinberg R A, (2009) The basics of epithelial-mesenchymal transition. J Clin Invest. 119: 1420–8
25. Steinestel K, Eder S, Schrader A J, and Steinestel J, (2014) Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 3: 17
26. Ozkumur E, Shah A M, Ciciliano J C, Emmink B L, Miyamoto D T, Brachtel E, Yu M, Chen P I, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott S L, Karabacak N M, Barber T A, Walsh J R, Smith K, Spuhler P S, Sullivan J P, Lee R J, Ting D T, Luo X, Shaw A T, Bardia A, Sequist L V, Louis D N, Maheswaran S, Kapur R, Haber D A, and Toner M, (2013) Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 5: 179ra47
27. Naume B, Borgen E, Tossvik S, Pavlak N, Oates D, and Nesland J M, (2004) Detection of isolated tumor cells in peripheral blood and in BM: Evaluation of a new enrichment method. Cytotherapy. 6: 244–52
28. Yang L, Lang J C, Balasubramanian P, Jatana K R, Schuller D, Agrawal A, Zborowski M, and Chalmers J J, (2009) Optimization of an enrichment process for circulating tumor cells from the blood of head and neck cancer patients through depletion of normal cells. Biotechnol Bioeng. 102: 521–34
29. Desitter I, Guerrouahen B S, Benali-Furet N, Wechsler J, Janne P A, Kuang Y, Yanagita M, Wang L, Berkowitz J A, Distel R J, and Cayre Y E, (2011) A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res. 31: 427–41
30. Chinen L T, de Carvalho F M, Rocha B M, Aguiar C M, Abdallah E A, Campanha D, Mingues N B, de Oliveira T B, Maciel M S, Cervantes G M, Dettino A L, Soares F A, Paterlini-Brechot P, and Fanelli M F, (2013) Cytokeratin-based CTC counting unrelated to clinical follow up. J Thorac Dis. 5: 593–9
31. Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K, Capron F, Franco D, Pazzagli M, Vekemans M, Lacour B, Brechot C, and Paterlini-Brechot P, (2000) Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol. 156: 57–63
32. Stott S L, Hsu C H, Tsukrov D I, Yu M, Miyamoto D T, Waltman B A, Rothenberg S M, Shah A M, Smas M E, Korir G K, Floyd F P, Jr. Gilman A J, Lord J B, Winokur D, Springer S, Irimia D, Nagrath S, Sequist L V, Lee R J, Isselbacher K J, Maheswaran S, Haber D A, and Toner M, (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA. 107: 18392–7
33. Chen J, Li J, and Sun Y, (2012) Microfluidic approaches for cancer cell detection, characterization, and separation. Lab Chip. 12: 1753–67
34. Cima I, Wen Yee C, Iliescu F S, Min Phyo W, Hon Lim K, Iliescu C, and Han Tan M, (2013) Label-free isolation of circulating tumor cells in microfluidic devices: Current research and perspectives. Biomicrofluidics. 7: 11810
35. Khoo B L, Warkiani M E, Tan D S, Bhagat A A, Irwin D, Lau D P, Lim A S, Lim K H, Krisna S S, Lim W T, Yap Y S, Lee S C, Soo R A, Han J, and Lim C T, (2014) Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One. 9: e99409
36. Nora Dickson M, Tsinberg P, Tang Z, Bischoff F Z, Wilson T, and Leonard E F, (2011) Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device. Biomicrofluidics. 5: 34119–3411915
37. Harb W, Fan A, Tran T, Danila D C, Keys D, Schwartz M, and Ionescu-Zanetti C, (2013) Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay. Transl Oncol. 6: 528–38
38. Bhagat A A, Bow H, Hou H W, Tan S J, Han J, and Lim C T, (2010) Microfluidics for cell separation. Med Biol Eng Comput. 48: 999–1014
39. Warkiani M E, Guan G, Luan K B, Lee W C, Bhagat A A, Chaudhuri P K, Tan D S, Lim W T, Lee S C, Chen P C, Lim C T, and Han J, (2014) Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip. 14: 128–37
40. Mateo J, Gerlinger M, Rodrigues D, and de Bono J S, (2014) The promise of circulating tumor cell analysis in cancer management. Genome Biol. 15: 448
41. Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, Bruce R, Nieva J, and Kuhn P, (2010) Cytomorphology of circulating colorectal tumor cells: A small case series. J Oncol. 2010: 861341
42. Cho E H, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko A H, Korn W M, Kolatkar A, Bethel K, and Kuhn P, (2012) Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 9: 016001
43. Marrinucci D, Bethel K, Kolatkar A, Luttgen M S, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko A H, Korn W M, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, and Kuhn P, (2012) Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 9: 016003
44. Wickman G, Julian L, and Olson M F, (2012) How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 19: 735–42
45. Krebs M G, Metcalf R L, Carter L, Brady G, Blackhall F H, and Dive C, (2014) Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 11: 129–44
46. Karantanos T, Corn P G, and Thompson T C, (2013) Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. 32: 5501–11
47. Phin S, Moore M W, and Cotter P D, (2013) Genomic Rearrangements of PTEN in Prostate Cancer. Front Oncol. 3: 240
48. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel J S, Pezaro C, Omlin A, Rodrigues D N, Flohr P, Tunariu N, J S d B, Demichelis F, and Attard G, (2014) Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 6: 254ra125
49. Lorente D, and de Bono J S, (2014) Molecular alterations and emerging targets in castration resistant prostate cancer. Eur J Cancer. 50: 753–64
50. Makkonen H, Kauhanen M, Jaaskelainen T, and Palvimo J J, (2011) Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol Cell Endocrinol. 331: 57–65
51. Waltering K K, Helenius M A, Sahu B, Manni V, Linja M J, Janne O A, and Visakorpi T, (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69: 8141–9
52. Macaulay I C, and Voet T, (2014) Single cell genomics: Advances and future perspectives. PLoS Genet. 10: e1004126
53. Lohr J G, Adalsteinsson V A, Cibulskis K, Choudhury A D, Rosenberg M, Cruz-Gordillo P, Francis J M, Zhang C Z, Shalek A K, Satija R, Trombetta J J, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen E M, Nakabayashi M, Lis R T, Lee G S, Li T, Chabot M S, Ly A, Taplin M E, Clancy T E, Loda M, Regev A, Meyerson M, Hahn W C, Kantoff P W, Golub T R, Getz G, and Boehm J S, (2014) Wholeexome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 32: 479–84
54. Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kress V, Heck M M, Andergassen U, Nawroth R, Gschwend J E, and Retz M, (2013) Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 139: 755–63
55. Bidard F C, Huguet F, Louvet C, Mineur L, Bouche O, Chibaudel B, Artru P, Desseigne F, Bachet J B, Mathiot C, Pierga J Y, and Hammel P, (2013) Circulating tumor cells in locally advanced pancreatic adenocarcinoma: The ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol. 24: 2057–61
56. Thorsteinsson M, and Jess P, (2011) The clinical significance of circulating tumor cells in non-metastatic colorectal cancer– a review. Eur J Surg Oncol. 37: 459–65
57. Pantel K, Deneve E, Nocca D, Coffy A, Vendrell J P, Maudelonde T, Riethdorf S, and Alix-Panabieres C, (2012) Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58: 936–40
58. Liu J F, Kindelberger D, Doyle C, Lowe A, Barry W T, and Matulonis U A, (2013) Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 131: 352–6
59. Boshuizen R, Kuhn P, and van den Heuvel M, (2012) Circulating tumor cells in non-small cell lung carcinoma. J Thorac Dis. 4: 456–8
60. Krebs M G, Hou J M, Sloane R, Lancashire L, Priest L, Nonaka D, Ward T H, Backen A, Clack G, Hughes A, Ranson M, Blackhall F H, and Dive C, (2012) Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches. J Thorac Oncol. 7: 306–15
61. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, Board R, Clack G, Hughes A, Blackhall F, Valle J W, and Dive C, (2012) A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 106: 508–16
62. Dittamore R, Krupa R, Louw J, Autio K, Arslan Z, Schreiber N, Anand A, Danila D, Bambury R, Bales N, Marrinucci D, and Scher HI, (2014) Frequency and characterization of Circulating Tumor Cell (CTC) populations in metastatic Castration Resistant Prostate Cancer (mCRPC). AACR-PCF Poster.
63. Kang Y, and Pantel K, (2013) Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell. 23: 573–81
64. Tam W L, and Weinberg R A, (2013) The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19: 1438–49
65. Hou J M, Krebs M G, Lancashire L, Sloane R, Backen A, Swain R K, Priest L J, Greystoke A, Zhou C, Morris K, Ward T, Blackhall F H, and Dive C, (2012) Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol. 30: 525–32
66. Aceto N, Bardia A, Miyamoto D T, Donaldson M C, Wittner B S, Spencer J A, Yu M, Pely A, Engstrom A, Zhu H, Brannigan B W, Kapur R, Stott S L, Shioda T, Ramaswamy S, Ting D T, Lin C P, Toner M, Haber D A, and Maheswaran S, (2014) Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 158: 1110–22
67. Labelle M, Begum S, and Hynes R O, (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 20: 576–90
68. Hou J M, Krebs M, Ward T, Sloane R, Priest L, Hughes A, Clack G, Ranson M, Blackhall F, and Dive C, (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol. 178: 989–96
69. Rhim A D, Mirek E T, Aiello N M, Maitra A, Bailey J M, McAllister F, Reichert M, Beatty G L, Rustgi A K, Vonderheide R H, Leach S D, and Stanger B Z, (2012) EMT and dissemination precede pancreatic tumor formation. Cell. 148: 349–61
70. Friedlander T W, Premasekharan G, and Paris P L, (2014) Looking back, to the future of circulating tumor cells. Pharmacol Ther. 142: 271–280
71. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki M A, Mavroudis D, Stournaras C, Georgoulias V, and Agelaki S, (2013) Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther. 12: 1886–95
72. Kandoth C, McLellan M D, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael J F, Wyczalkowski M A, Leiserson M D, Miller C A, Welch J S, Walter M J, Wendl M C, Ley T J, Wilson R K, Raphael B J, and Ding L, (2013) Mutational landscape and significance across 12 major cancer types. Nature. 502: 333–9
73. Gerlinger M, Rowan A J, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald N Q, Butler A, Jones D, Raine K, Latimer C, Santos C R, Nohadani M, Eklund A C, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal P A, and Swanton C, (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366: 883–92
74. Zhang J, Fujimoto J, Zhang J, Wedge D C, Song X, Zhang J, Seth S, Chow C W, Cao Y, Gumbs C, Gold K A, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William W N, Lee J J, Heymach J V, Hong W K, Swisher S, Wistuba II and Futreal P A, (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 346: 256–9
75. Crockford A, Jamal-Hanjani M, Hicks J, and Swanton C, (2014) Implications of intratumour heterogeneity for treatment stratification. J Pathol. 232: 264–73
76. Meacham C E, and Morrison S J, (2013) Tumour heterogeneity and cancer cell plasticity. Nature. 501: 328–337
77. Bedard P L, Hansen A R, Ratain M J, and Siu L L, (2013) Tumour heterogeneity in the clinic. Nature. 501: 355–364
78. Shrager J, and Tenenbaum J M, (2014) Rapid learning for precision oncology. Nat Rev Clin Oncol. 11: 109–18
79. Crowley E, di Nicolantonio F, Loupakis F, and Bardelli A, (2013) Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 10: 472–84